A collaboration between the University of Pittsburgh and the University of Pennsylvania has led to the development of bait oligonucleotides that inhibit and reverse TDP-43 inclusions associated with ALS, FTD, and Alzheimer's Disease.
This technology combines vascular cell types, such as endothelial cells and pericytes, within a self-organizing 3D brain organoid structure that develops a functional blood-brain barrier.